Overview

• NextCure Q3 net loss decreases compared to same period last year

• Company advances ADC programs with U.S. enrollment and FDA clearance for protocol amendment

• Financial resources expected to fund operations into mid-2026

Outlook

• NextCure's current financial resources expected to last into mid-2026

Result Drivers

• ADC PROGRAM ADVANCEMENT - NextCure progressed ADC programs with U.S. enrollment for SIM0505 and FDA clearance for LNCB74 protocol amendment

• Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024.

• FINANCIAL RESOURCE MANAGEMENT - Cash reserves decreased due to operational funding and license fees, but expected to fund operations into mid-2026

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for NextCure Inc is $17.50, about 44.9% above its November 4 closing price of $9.64

Press Release: ID:nGNX4Ps7Pr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)